Document is current

Article History

Received: 6 September 2024

Accepted: 11 November 2024

First Online: 9 December 2024

Declarations

:

: HG has received Honoraria/fees from Chugai, Novartis, BMS, Gilead and AbbVie and research funding from Kyowa-Kirin, BMS, Symbio and Sanofi. TK has received Lecture/Honoraria fees from Ono Pharmaceutical and Janssen. YM has received Lecture/Honoraria fees from Chugai Pharma and F. Hoffmann-La Roche Ltd; Research grants from BMS and Eizai. KK has received annual profit from shares from Asahi Genomics; Lecture/Honoraria funding from Novartis, Chugai Pharmaceutical, and Meiji Seika Pharma; research funding from Otsuka Pharmaceutical, Chordia Therapeutics, Chugai Pharmaceutical, Takeda Pharmaceutical, and Meiji Seika Pharma; research grants from Eisai, Kyowa Kirin, Otsuka Pharmaceutical, Chugai Pharmaceutical, Mochida Pharmaceutical, JCR Pharmaceuticals, and Asahi Kasei Pharma. YO has received Lecture/Honoraria fees from Novartis; research funding from Novartis, Janssen, AbbVie, Chugai, Otsuka Pharmacue Tical and IQVIA; research grant from Mochida Pharmaceutical. NK has nothing to declare. KS has nothing to declare. TU has nothing to declare. YK is an employee of Chugai. AK is an employee of Chugai. JS is an employee of Chugai. TT has received research funds and research grants from Chugai.

: The protocol was approved by the relevant institutional review boards. The trial was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization guidelines for Good Clinical Practice, and applicable laws and regulations. All patients provided written informed consent.